By: Hannah Slater From: cancernetwork.com Results from a subgroup of the TAILORx trial, published in the Journal of Clinical Oncology, suggested that adjuvant chemoendocrine therapy is associated with significantly greater cancer-related cognitive impairment (CRCI) compared with endocrine therapy alone among women with breast cancer at 3 and 6 months.1 However, these differences receded over time, with no significant differences observed at …
-
-
Why I Can’t Write Your Breast Cancer Story for You
-
Moving to a Distant Location as a Breast Cancer Survivor
-
Getting a Second Opinion After a Breast Cancer Diagnosis
-
Dealing with the Side Effects of Breast Cancer Treatments
-
Why Would You Tell a Breast Cancer Survivor What to Do?
